Fig. 2

B cell subsets in spleen from pristane-treated vs. PBS treated mice. Spleen cells from pristane-treated (1 year) and age-matched PBS treated mice were stained with anti-CD19, CD138, IgM, and IgD antibodies and analyzed by flow cytometry. a Gating strategy for CD19⁺CD138⁺ plasmablasts (PB) and CD19^+/−CD138⁺⁺ plasma cells (PC) (top) and CD19⁺CD138⁻IgM⁺IgD⁺ naïve B cells (NB), and CD19⁺CD138⁻IgM⁻IgD⁻ switched-memory B cells (sMB) (bottom) are shown on the left. Percentages of PB and PC in spleen from pristane-treated and untreated mice are on the top right and percentages of NB and sMB in CD19⁺CD138⁻ cells are on the bottom right. b The gating strategy for CD19⁺CD138⁻IgM⁻IgD⁺ and CD19⁺CD138⁻IgD⁺ cells is the same as a. The percentage of CD19⁺CD138⁻IgM⁻IgD⁺ and CD19⁺CD138⁻IgD⁺ cells in CD19⁺CD138⁻ cells in spleens from pristane-treated and untreated mice are shown: *p <0.05; **p <0.01, Mann–Whitney test